SLC5A2 and type 2 diabetes mellitus: Recent years have witnessed the emergence of evidence from phase III randomised clinical trials of the direct cardiovascular benefits of sodium-glucose-cotransporter 2 (SGLT2) inhibitors among patients with T2DM: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients - Removing Excess Glucose (EMPA-REG OUTCOME) study; and the Canagliflozin Cardiovascular Assessment Study (CANVAS) study12,13.